N/A
N=214
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases
Stable Angina
Bottom Line
View on ClinicalTrials.gov: NCT02179047 ↗Enrolled (actual)
214
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Biomarker Titer of Patients With Coronary Artery Disease — 13; 5; 60; 0.5 tilter — p=0.002
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- coronary angiography (Procedure)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Taipei City Hospital
- Primary completion
- May 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Biomarker Titer of Patients With Coronary Artery Disease |
13; 5; 60; 0.5; 0.16; 184 | 0.002 sig |
| PRIMARY Biomarker of Healthy Subjects(Placebo) |
12; 4; 52; 0.1; 0.12; 121 | 0.002 sig |
| PRIMARY SYNTAX(SYNergy Between Percutaneous Coronary Intervention With TAXus) for Stable Angina Receveived Coronary Angiogram |
22; 19; 32; 28; 33; 19 | 0.001 sig |
Summary
Through the literature review , we pick out a series of forward-looking biological indicators as follows :
1. NGAL
2. Cystatin C:
3. Galectin-3:
4. Copeptin:
5. MR-Pro ANP:
6. sST2:
Eligibility Criteria
Inclusion Criteria
- stable angina who eligible for coronary angiography after non-invasive stress test.
Exclusion Criteria
- intolerance to procedure or contarst medium.
Data sourced from ClinicalTrials.gov (NCT02179047). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.